The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
5-(5-chloro-2-hydroxybenzylidene)-3-(3-nitrobenzyl)thiazolidine-2,4-dione ID: ALA2011396
PubChem CID: 2284978
Max Phase: Preclinical
Molecular Formula: C17H11ClN2O5S
Molecular Weight: 390.80
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: O=C1S/C(=C\c2cc(Cl)ccc2O)C(=O)N1Cc1cccc([N+](=O)[O-])c1
Standard InChI: InChI=1S/C17H11ClN2O5S/c18-12-4-5-14(21)11(7-12)8-15-16(22)19(17(23)26-15)9-10-2-1-3-13(6-10)20(24)25/h1-8,21H,9H2/b15-8-
Standard InChI Key: BBRNHDJYYOJNPV-NVNXTCNLSA-N
Molfile:
RDKit 2D
26 28 0 0 0 0 0 0 0 0999 V2000
8.2736 -20.2500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.2724 -21.0773 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.9872 -21.4902 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.7037 -21.0769 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.7008 -20.2463 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.9854 -19.8372 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.4137 -19.8311 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.1294 -20.2410 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.1475 -21.0697 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
11.9377 -21.3068 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.4074 -20.6284 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.9073 -19.9723 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1460 -19.1826 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.2321 -20.6096 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.6608 -21.3145 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.2605 -22.0349 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.6885 -22.7393 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.5142 -22.7209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9100 -21.9922 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.4798 -21.2908 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.7392 -21.9711 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.1328 -21.2461 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.1703 -22.6745 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.9830 -19.0122 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.9870 -22.3152 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
12.2104 -22.0854 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6 1 1 0
12 13 2 0
1 2 2 0
10 26 2 0
5 7 1 0
11 14 1 0
3 4 2 0
14 15 1 0
7 8 2 0
15 16 2 0
8 9 1 0
16 17 1 0
17 18 2 0
4 5 1 0
18 19 1 0
2 3 1 0
19 20 2 0
20 15 1 0
5 6 2 0
9 10 1 0
10 11 1 0
21 22 2 0
21 23 1 0
19 21 1 0
11 12 1 0
6 24 1 0
12 8 1 0
3 25 1 0
M CHG 2 21 1 23 -1
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 390.80Molecular Weight (Monoisotopic): 390.0077AlogP: 4.19#Rotatable Bonds: 4Polar Surface Area: 100.75Molecular Species: NEUTRALHBA: 6HBD: 1#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.57CX Basic pKa: ┄CX LogP: 4.04CX LogD: 4.01Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.48Np Likeness Score: -1.97
References 1. Brvar M, Perdih A, Hodnik V, Renko M, Anderluh G, Jerala R, Solmajer T.. (2012) In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B., 20 (8): [PMID:22444877 ] [10.1016/j.bmc.2012.02.052 ] 2. Al-Asri J, Fazekas E, Lehoczki G, Perdih A, Görick C, Melzig MF, Gyémánt G, Wolber G, Mortier J.. (2015) From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors., 23 (20): [PMID:26395057 ] [10.1016/j.bmc.2015.09.007 ]